Compositions and Methods for the Treatment of Presbyopia (2019)
Lenz Therapeutics Operations, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/743,720, filed Oct 10, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,273,150 | Compositions and Methods for the Treatment of Presbyopia In force · High confidence UsedRemaining | Lenz Therapeutics Operations, Inc. | In force | High confidence | ||
| US 10,836,760 | Compositions and Methods for the Treatment of Presbyopia In force · High confidence | Lenz Therapeutics Operations, Inc. | In force | High confidence | ||
| US 12,128,036 | Compositions and Methods for Storage Stable Ophthalmic Drugs In force · Medium confidence | Lenz Therapeutics Operations, Inc. | In force | Medium confidence | ||
| US 12,533,347 | Compositions and Methods for Storage Stable Ophthalmic Drugs In force · Medium confidence | Lenz Therapeutics Operations, Inc. | In force | Medium confidence | ||
| Application 17/242,398 | Compositions and Methods for Storage Stable Ophthalmic Drugs Abandoned Abandoned Sep 29, 2023 | Lenz Therapeutics Operations, Inc. | Abandoned | Abandoned Sep 29, 2023 | ||
| Application 19/417,031 | Compositions and Methods for Storage Stable Ophthalmic Drugs Pending Not granted | Lenz Therapeutics Operations, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Lenz Therapeutics Operations, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.